We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The collaboration builds on an existing long term relationship between the parties whereby FORMA has accessed Ubiquigent’s DUBprofiler™ platform for the screening of test compounds
The collaboration builds on an existing long term relationship between the parties whereby FORMA has accessed Ubiquigent’s DUBprofiler™ platform for the screening of test compounds
FORMA Therapeutics and Arpeggio Biosciences today announced a collaboration to utilize Arpeggio Biosciences’ proprietary technology to supplement FORMA’s analysis of the biological effects of its potential drug candidates.